Accès ouvert déclaré
2020
article
HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study
Colette Smit, Anders Boyd, Bart Rijnders, Thijs van de Laar, Eliane M.S. Leyten, Wouter F.W. Bierman, Kees Brinkman, Mark A. A. Claassen, Jan den Hollander, Anne Boerekamps, Astrid M. Newsum, Janke Schinkel, Maria Prins, Joop E. Arends, Eline Op de Coul, Marc van der Valk, Peter Reiss, Suzanne E. Geerlings, Abraham Goorhuis, Joppe W. Hovius, B. Lempkes, F.J.B. Nellen, T. van der Poll, Jan M. Prins, Michèle van Vugt, W. Joost Wiersinga, F.W.M.N. Wit, Marlies van Duinen, J. van Eden, A. Hazenberg, A M H van Hes, F J J Pijnappel, S Smalhout, Annouschka M. Weijsenfeld, Suzanne Jurriaans, Nicole Back, Hans L. Zaaijer, B. Berkhout, Marion Cornelissen, C. Schinkel, Katja C. Wolthers, Edgar J.G. Peters, Reshma Autar, Marije K. Bomers, Kim Sigaloff, M. Heitmuller, Liedewij Laan, C. Wim Ang, Robin van Houdt, Marcel Jonges, Maarten van den Berge, Arjan Stegeman, S. Baas, L. Hage de Looff, A. G. M. Buiting, Anne Q. Reuwer, Jacobien Veenemans, Bas Wintermans, M.J.H. Pronk, Heidi Ammerlaan, D. N. J. van den Bersselaar, E.S. de Munnik, Birgit Deiman, A R Jansz, Volkher Scharnhorst, Jeroen H. T. Tjhie, M.C.A. Wegdam, Arne van Eeden, Jeannine F. Nellen, W. Brokking, L. Elsenburg, H. Nobel, M.E.E. van Kasteren, Marvin A. H. Berrevoets, Annemarie E. Brouwer, Andrew L. Adams, R. van Erve, B.A.F.M. de Kruijf-van de Wiel, S. Keelan-Phaf, B. van de Ven, J.L. Murck, T.E.M.S. de Vries-Sluijs, Hannelore I. Bax, Eric C. M. Van Gorp, N. C. de Jong-Peltenburg, Martim Melo, Els van Nood, Jan Nouwen, Casper Rokx, Carolina A. M. Schurink, Lennert Slobbe, Annelies Verbon, N. Bassant, J.E.A. van Beek, M. Vriesde, L.M. van Zonneveld, Joris R. de Groot, Charles A. Boucher, Marion Koopmans, Jeroen J. A. van Kampen, Judith Branger, Reuben Douma, A.S. Cents-Bosma, C.J.H.M. Duijf-van de Ven, Emile F. Schippers, Cees van Nieuwkoop, J.M. van IJperen, J. Geilings, Nathalie D. van Burgel, G. van der Hut, L. B. S. Gelinck, Femke Mollema, S. Davids-Veldhuis, C. Tearno, G.S. Wildenbeest, E. Heikens, P. H. P. Groeneveld, J.W. Bouwhuis, A.J.J. Lammers, S. Kraan, A. G. W. van Hulzen, M.S.M. Kruiper, G.L. van der Bliek, Petra Bor, S.B. Debast, Gertjan H.J. Wagenvoort, Frank P. Kroon, Mark de Boer, H. Jolink, Merel M. C. Lambregts, Anna H.E. Roukens, Henk Scheper, W. Dorama, Natasja van Holten, Eric C. J. Claas, Els Wessels, Jan G. den Hollander, C.J. Brouwer, Jesper Smit, D. Struik-Kalkman, T.G.C.M. van Niekerk, Rafika Moussaoui, Katalin Pogány, Oscar Pontesilli, S.H. Lowe, Astrid M. L. Oude Lashof, Dirk Posthouwer, Marlies E van Wolfswinkel, Robin Ackens, Kristina Burgers, J. Schippers, B. Weijenberg-Maes, Inge H. M. van Loo, Thomas Havenith, Marit G. A. van Vonderen, L.M. Kampschreur, S. M. Faber, R. Steeman-Bouma, A. Al Moujahid, G. J. Kootstra, Corine Delsing, Matthijs Plas, L. Scheiberlich, W. Kortmann, G. van Twillert, R. Renckens, D. Ruiter-Pronk, F.A. van Truijen-Oud, J. W. T. Cohen Stuart, E.R. Jansen, Marieke Hoogewerf, Wouter Rozemeijer, W.A. van der Reijden, J. C. Sinnige, G.E.L. van den Berk, W Blok, Kamilla D. Lettinga, Marina de Regt, W.E.M. Schouten, Janneke E. Stalenhoef, Jan A. Veenstra, S.M.E. Vrouenraets, H. Blaauw, G.F. Geerders, M.J. Kleene, Marjolein Kok, M. Knapen, I.B. van der Meché, E. Mulder-Seeleman, A.J.M. Toonen, S. Wijnands, E. Wttewaal, David Kwa, Reinout van Crevel, A. Dofferhoff, H.J.M. ter Hofstede, Jacobien J. Hoogerwerf, Monique Keuter, Olivier Richel, M. Albers, K.J.T. Grintjes-Huisman, M. de Haan, M. Marneef, R. Strik-Albers, Janette Rahamat‐Langendoen, Foekje F. Stelma, David M. Burger, Elisabeth H. Gisolf, R.J. Hassing, G. ter Beest, P.H.M. van Bentum, Nienke Langebeek, R. Tiemessen, C.M.A. Swanink, S.F.L. van Lelyveld, Robert Soetekouw, L.M.M. van der Prijt, J. van der Swaluw, N. Bermon, Ruud Jansen, Bjorn L. Herpers, Dick Veenendaal, D.W.M. Verhagen, Fanny N. Lauw, Michelle Broekhuizen, Michiel P. van Wijk, Margreet Bakker, Johanneke Kleinnijenhuis, E. Kloeze, Ananja Middel, Douwe F. Postma, Ymkje Stienstra, Marjan Wouthuyzen‐Bakker, André Boonstra, H. de Jonge, D.A. de Weerd, Hubert G.M. Niesters, Coretta van Leer‐Buter, Marjolein Knoester, A. I. M. Hoepelman, Roos E. Barth, A.H.W. Bruns, Pauline M. Ellerbroek, Tania Mudrikova, Jan Jelrik Oosterheert, E.M. Schadd, Berend J. van Welzen, K. Aarsman, B.M.G. Griffioen-van Santen, I. de Kroon, M. van Berkel, C S A M van Rooijen, R. Schuurman, F. Verduyn-Lunel, Annemarie M. J. Wensing, S Zaheri, Daniela Bezemer, A.I. van Sighem, M Hillebregt, A. de Jong, T.J. Woudstra, D.P. Bergsma, Roelien A. M. Meijering, Linette Sande, T. Rutkens, Stefan van der Vliet, C.P.G.M. de Groot, Marjan van den Akker, Y. Bakker, A el Berkaoui, M. Bezemer, N.M. Brétin, E.A. Djoechro, M. Groters, E Kruijne, K.J. Lelivelt, C.R.E. Lodewijk, E.G.A. Lucas, L. Munjishvili, Fleur P. Paling, B Peeck, Cornelis L. P. van de Ree, R. Regtop, Y M C Ruijs, Maartje Schoorl, P.P. Schnörr, A. Scheigrond, E. Tuijn, Kirsten Visser, E.C.M. Witte
74Citations signalées — pas une note de qualité
15Institutions déclarées
1Pays d’affiliation déclarés
Résumé fourni par la source
BACKGROUND: In the Netherlands, access to direct-acting antivirals (DAAs) against hepatitis C virus (HCV) has been unrestricted for chronic infection since 2015. We evaluated whether the nationwide incidence of HCV infections in individuals with HIV has changed since 2015. METHODS: In this retrospective cohort study, data from the ATHENA cohort of people with HIV aged 18 years or older attending any of the 24 HIV treatment centres in the Netherlands between 2000 and 2019 were assessed. We used parametric proportional hazards models with a piecewise exponential survival function to model HCV primary infection and reinfection incidence per 1000 person-years. FINDINGS: Of the 23 590 individuals without previous HCV infection, 1269 cases of HCV primary infection were documented (incidence 5·2 per 1000 person-years [95% CI 5·0-5·5]). The highest incidence was observed in men who have sex with men (MSM; 7·7 per 1000 person-years [7·3-8·2]) and was lower in people who inject drugs (PWID; 1·7 per 1000 person-years [0·7-4·1]) and other key populations (1·0 per 1000 person-years [0·8-1·2]). In MSM, incidence increased in 2007 to 14·3 per 1000 person-years and fluctuated between 8·7 and 13·0 per 1000 person-years from 2008 to 2015. In 2016, incidence declined to 6·1 cases per 1000 person-years and remained steady between 4·1 and 4·9 per 1000 person-years from 2017 to 2019. Of the 1866 individuals with a previous HCV infection, 274 reinfections were documented (incidence 26·9 per 1000 person-years [95% CI 23·9-30·3]). The highest incidence rate was observed in MSM (38·5 per 1000 person-years [33·9-43·7]) and was lower in PWID (10·9 per 1000 person-years [3·5-33·8]) and other key populations (8·9 per 1000 person-years [6·3-12·5]). In MSM, reinfection incidence fluctuated between 38·0 and 88·9 per 1000 person-years from 2006 to 2015, reaching 55·6 per 1000 person-years in 2015. In 2016, reinfection incidence declined to 41·4 per 1000 person-years, followed by further decreases to 24·4 per 1000 person-years in 2017 and 11·4 per 1000 person-years in 2019. INTERPRETATION: The sharp decline in HCV incidence in MSM with HIV shortly after restrictions on DAAs were lifted suggests a treatment-as-prevention effect. HCV incidence was already low in PWID and other groups before unrestricted access. Ongoing HCV transmission is occurring in MSM, as illustrated by a declining but high rate of reinfection, stressing the need for additional preventive measures. FUNDING: Dutch Ministry of Health, Welfare, and Sport.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study
- Date Crossref
- 01/02/2021
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.
Institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Sujets associés
Hepatitis C virus researchHIV/AIDS drug development and treatmentHIV-related health complications and treatments